Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma
Open Access
- 20 April 2009
- Vol. 115 (9), 1892-1898
- https://doi.org/10.1002/cncr.24204
Abstract
BACKGROUND: Standard intrathecal chemotherapy for lymphomatous meningitis (LM) is limited by the short cerebrospinal half‐lives of the agents used, necessitating frequent administration. Liposomal cytarabine (DepoCyte) has an extended half‐life that permits administration at 2‐ to 4‐weekly intervals. METHODS: Patients with LM who underwent treatment with liposomal cytarabine at treatment centers in Spain between 2004 and 2007 were identified. Data on demographics, treatment, and outcomes were extracted from medical notes and entered, retrospectively, into a database for analysis. RESULTS: Data on 55 patients with lymphoma (mainly stage IV) and LM were entered into the database. Most patients (n = 36) had diffuse large B‐cell lymphoma. The median number of cycles of liposomal cytarabine received was 4 (range, 1‐10), and the median follow‐up period was 124 days. Complete and partial neurologic responses were achieved in 27 and 12 patients, respectively (overall response rate, 72%), all of whom also showed a cytological response, except for 5 with initially negative cytology. Median time to neurologic progression among responders was 105.5 days. Liposomal cytarabine was generally well tolerated; headache was the most commonly reported adverse effect (n = 17). CONCLUSIONS: Liposomal cytarabine is effective and well tolerated in the treatment of LM, and should be considered as an agent of choice for the treatment of this complication. Cancer 2009. © 2009 American Cancer Society.Keywords
This publication has 8 references indexed in Scilit:
- Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemiaBlood, 2007
- Intrathecal liposomal cytarabine for prevention of meningeal disease in patients with acute lymphocytic leukemia and high-grade lymphomaLeukemia & Lymphoma, 2007
- Leukemic and lymphomatous meningitis: incidence, prognosis and treatmentJournal of Neuro-Oncology, 2005
- Leptomeningeal Metastases: Current Concepts and Management GuidelinesJournal of the National Comprehensive Cancer Network, 2005
- Quality‐of‐life–adjusted survival comparison of sustained‐release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitisCancer, 2003
- Randomized Trial of a Slow-Release Versus a Standard Formulation of Cytarabine for the Intrathecal Treatment of Lymphomatous MeningitisJournal of Clinical Oncology, 1999
- Neoplastic MeningitisCNS Drugs, 1998
- Pharmacokinetics of Intralumbar DTC-101 for the Treatment of Leptomeningeal MetastasesArchives of Neurology, 1995